Mauricio Moreno
Concepts (309)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Free Tissue Flaps | 14 | 2025 | 63 | 7.180 |
Why?
| | Head and Neck Neoplasms | 15 | 2025 | 289 | 6.210 |
Why?
| | Mandibular Reconstruction | 3 | 2024 | 15 | 1.840 |
Why?
| | Neck Dissection | 6 | 2021 | 29 | 1.720 |
Why?
| | Retrospective Studies | 30 | 2025 | 6694 | 1.590 |
Why?
| | Length of Stay | 4 | 2023 | 673 | 1.560 |
Why?
| | Neck | 4 | 2021 | 97 | 1.420 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2024 | 331 | 1.400 |
Why?
| | Laryngectomy | 3 | 2024 | 27 | 1.360 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 639 | 1.250 |
Why?
| | Middle Aged | 36 | 2025 | 13133 | 1.250 |
Why?
| | Postoperative Complications | 10 | 2025 | 1065 | 1.150 |
Why?
| | Aged | 29 | 2025 | 10242 | 1.060 |
Why?
| | Salvage Therapy | 2 | 2024 | 137 | 1.000 |
Why?
| | Aged, 80 and over | 16 | 2025 | 3449 | 0.960 |
Why?
| | Critical Pathways | 3 | 2023 | 36 | 0.940 |
Why?
| | Male | 37 | 2025 | 26874 | 0.930 |
Why?
| | Female | 39 | 2025 | 28277 | 0.910 |
Why?
| | Pharyngectomy | 1 | 2024 | 2 | 0.870 |
Why?
| | Time-to-Treatment | 2 | 2025 | 77 | 0.860 |
Why?
| | Skull | 1 | 2024 | 77 | 0.850 |
Why?
| | Scalp | 1 | 2024 | 43 | 0.850 |
Why?
| | Laryngeal Neoplasms | 1 | 2024 | 43 | 0.840 |
Why?
| | Mandible | 2 | 2024 | 25 | 0.840 |
Why?
| | Skin Neoplasms | 4 | 2024 | 496 | 0.840 |
Why?
| | Humans | 52 | 2025 | 52441 | 0.820 |
Why?
| | Operative Time | 1 | 2023 | 76 | 0.820 |
Why?
| | Surgery, Computer-Assisted | 1 | 2023 | 54 | 0.800 |
Why?
| | Thyroidectomy | 3 | 2021 | 61 | 0.790 |
Why?
| | Treatment Outcome | 19 | 2025 | 5508 | 0.780 |
Why?
| | Head | 2 | 2021 | 70 | 0.760 |
Why?
| | Adult | 25 | 2025 | 14205 | 0.720 |
Why?
| | Intraoperative Complications | 2 | 2021 | 113 | 0.720 |
Why?
| | Intraoperative Care | 1 | 2021 | 51 | 0.720 |
Why?
| | Chylothorax | 1 | 2021 | 18 | 0.690 |
Why?
| | Hypotension | 1 | 2021 | 63 | 0.690 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 81 | 0.680 |
Why?
| | Venous Thrombosis | 1 | 2021 | 89 | 0.670 |
Why?
| | Morbidity | 1 | 2021 | 137 | 0.660 |
Why?
| | Health Status Indicators | 2 | 2019 | 81 | 0.660 |
Why?
| | Paranasal Sinus Neoplasms | 2 | 2010 | 19 | 0.650 |
Why?
| | Thyroid Neoplasms | 2 | 2012 | 111 | 0.640 |
Why?
| | Naproxen | 1 | 2019 | 7 | 0.640 |
Why?
| | Orthognathic Surgical Procedures | 1 | 2019 | 2 | 0.630 |
Why?
| | Reoperation | 1 | 2021 | 463 | 0.620 |
Why?
| | Edema | 1 | 2019 | 63 | 0.600 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 123 | 0.580 |
Why?
| | Health Resources | 1 | 2019 | 71 | 0.570 |
Why?
| | Academic Medical Centers | 2 | 2019 | 151 | 0.540 |
Why?
| | Radiotherapy, Adjuvant | 5 | 2025 | 65 | 0.540 |
Why?
| | Melanoma | 2 | 2010 | 272 | 0.520 |
Why?
| | Thigh | 2 | 2015 | 34 | 0.520 |
Why?
| | Surgical Flaps | 2 | 2023 | 111 | 0.490 |
Why?
| | Patient Discharge | 2 | 2019 | 320 | 0.480 |
Why?
| | Databases, Factual | 2 | 2019 | 721 | 0.450 |
Why?
| | Carcinoma, Papillary | 2 | 2012 | 49 | 0.420 |
Why?
| | Parathyroidectomy | 2 | 2012 | 46 | 0.420 |
Why?
| | Video-Assisted Surgery | 1 | 2013 | 1 | 0.410 |
Why?
| | Tissue and Organ Harvesting | 1 | 2013 | 25 | 0.400 |
Why?
| | Soft Tissue Injuries | 1 | 2013 | 17 | 0.400 |
Why?
| | Neck Injuries | 1 | 2013 | 21 | 0.400 |
Why?
| | Endoscopy | 1 | 2013 | 126 | 0.380 |
Why?
| | Prognosis | 4 | 2024 | 2100 | 0.370 |
Why?
| | Speech, Esophageal | 1 | 2010 | 1 | 0.340 |
Why?
| | Combined Modality Therapy | 3 | 2024 | 641 | 0.340 |
Why?
| | Graft Survival | 3 | 2025 | 157 | 0.340 |
Why?
| | Parathyroid Neoplasms | 1 | 2010 | 26 | 0.330 |
Why?
| | Palatal Obturators | 1 | 2010 | 1 | 0.330 |
Why?
| | Maxilla | 1 | 2010 | 14 | 0.330 |
Why?
| | Neoplasm Staging | 4 | 2024 | 768 | 0.330 |
Why?
| | Nose Neoplasms | 1 | 2010 | 3 | 0.330 |
Why?
| | Carcinoma, Merkel Cell | 3 | 2016 | 41 | 0.330 |
Why?
| | Nasal Mucosa | 1 | 2010 | 19 | 0.320 |
Why?
| | Adolescent | 10 | 2019 | 6713 | 0.320 |
Why?
| | Preoperative Care | 1 | 2011 | 173 | 0.310 |
Why?
| | Adenoma | 1 | 2010 | 114 | 0.310 |
Why?
| | Follow-Up Studies | 6 | 2023 | 2294 | 0.300 |
Why?
| | Deglutition | 2 | 2024 | 45 | 0.290 |
Why?
| | Young Adult | 7 | 2019 | 4346 | 0.290 |
Why?
| | Fibula | 2 | 2024 | 23 | 0.260 |
Why?
| | Colitis, Ulcerative | 2 | 2018 | 67 | 0.260 |
Why?
| | Crohn Disease | 2 | 2018 | 115 | 0.240 |
Why?
| | Pain, Postoperative | 3 | 2022 | 169 | 0.230 |
Why?
| | Osteoradionecrosis | 1 | 2024 | 6 | 0.220 |
Why?
| | Mandibular Diseases | 1 | 2024 | 11 | 0.220 |
Why?
| | Comorbidity | 2 | 2019 | 637 | 0.220 |
Why?
| | Adenocarcinoma | 2 | 2023 | 403 | 0.220 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 83 | 0.220 |
Why?
| | Foxes | 1 | 2024 | 1 | 0.220 |
Why?
| | Pharyngeal Diseases | 1 | 2024 | 12 | 0.220 |
Why?
| | Cutaneous Fistula | 1 | 2024 | 14 | 0.220 |
Why?
| | Chromosomes | 1 | 2024 | 29 | 0.210 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.210 |
Why?
| | Physical Examination | 1 | 2024 | 98 | 0.210 |
Why?
| | Adenoma, Pleomorphic | 1 | 2023 | 3 | 0.210 |
Why?
| | Paranasal Sinuses | 1 | 2023 | 15 | 0.210 |
Why?
| | Salivary Gland Neoplasms | 1 | 2023 | 7 | 0.210 |
Why?
| | Carcinoma, Ductal | 1 | 2023 | 7 | 0.210 |
Why?
| | Scapula | 1 | 2023 | 16 | 0.200 |
Why?
| | Forearm | 1 | 2023 | 29 | 0.200 |
Why?
| | Sinusitis | 1 | 2023 | 42 | 0.200 |
Why?
| | Enteral Nutrition | 1 | 2024 | 154 | 0.200 |
Why?
| | Deglutition Disorders | 1 | 2024 | 76 | 0.200 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 122 | 0.200 |
Why?
| | Tramadol | 1 | 2022 | 30 | 0.190 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 871 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2024 | 1140 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2023 | 238 | 0.180 |
Why?
| | Microsurgery | 1 | 2021 | 32 | 0.180 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 6 | 0.180 |
Why?
| | Anastomosis, Surgical | 1 | 2021 | 69 | 0.180 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 212 | 0.170 |
Why?
| | Gastrointestinal Agents | 2 | 2018 | 41 | 0.170 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 370 | 0.170 |
Why?
| | Indocyanine Green | 2 | 2011 | 29 | 0.170 |
Why?
| | Laser Therapy | 2 | 2011 | 74 | 0.170 |
Why?
| | Robotics | 1 | 2021 | 43 | 0.170 |
Why?
| | Cohort Studies | 2 | 2019 | 1576 | 0.170 |
Why?
| | Health Services Accessibility | 1 | 2025 | 444 | 0.170 |
Why?
| | Reproducibility of Results | 4 | 2023 | 1223 | 0.160 |
Why?
| | Odds Ratio | 1 | 2021 | 563 | 0.160 |
Why?
| | Acetaminophen | 1 | 2022 | 272 | 0.160 |
Why?
| | Prospective Studies | 5 | 2024 | 2433 | 0.160 |
Why?
| | Ultrasonography | 2 | 2012 | 416 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2022 | 601 | 0.150 |
Why?
| | Hospital Costs | 1 | 2019 | 73 | 0.140 |
Why?
| | Quality of Life | 2 | 2019 | 893 | 0.140 |
Why?
| | Drug Monitoring | 1 | 2018 | 81 | 0.140 |
Why?
| | Postoperative Care | 1 | 2019 | 104 | 0.140 |
Why?
| | Graft Rejection | 1 | 2019 | 166 | 0.140 |
Why?
| | Arkansas | 2 | 2025 | 2013 | 0.140 |
Why?
| | Analysis of Variance | 1 | 2019 | 558 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 615 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 230 | 0.130 |
Why?
| | Patient Readmission | 1 | 2019 | 249 | 0.130 |
Why?
| | Benzoxazoles | 1 | 2016 | 12 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 938 | 0.120 |
Why?
| | United States | 2 | 2019 | 5215 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myb | 1 | 2015 | 8 | 0.120 |
Why?
| | Cell Proliferation | 2 | 2016 | 1013 | 0.110 |
Why?
| | Pyrimidines | 1 | 2016 | 199 | 0.110 |
Why?
| | Regression Analysis | 2 | 2012 | 400 | 0.110 |
Why?
| | Transcription Factors | 2 | 2015 | 570 | 0.100 |
Why?
| | Apoptosis | 2 | 2016 | 1120 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2015 | 247 | 0.100 |
Why?
| | Child | 4 | 2018 | 7194 | 0.100 |
Why?
| | Skin Transplantation | 1 | 2013 | 43 | 0.100 |
Why?
| | Osteocalcin | 1 | 2012 | 44 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 287 | 0.090 |
Why?
| | Survival | 1 | 2012 | 13 | 0.090 |
Why?
| | Hyperparathyroidism, Primary | 1 | 2012 | 35 | 0.090 |
Why?
| | Recurrence | 2 | 2012 | 680 | 0.090 |
Why?
| | Iodine Radioisotopes | 1 | 2012 | 33 | 0.090 |
Why?
| | Leukoplakia, Oral | 1 | 2011 | 6 | 0.090 |
Why?
| | Aminolevulinic Acid | 1 | 2011 | 9 | 0.090 |
Why?
| | Lasers, Dye | 1 | 2011 | 10 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2012 | 73 | 0.090 |
Why?
| | Photosensitizing Agents | 1 | 2011 | 20 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 396 | 0.090 |
Why?
| | Hospital Mortality | 1 | 2014 | 451 | 0.090 |
Why?
| | Thyroid Gland | 2 | 2022 | 77 | 0.090 |
Why?
| | Infrared Rays | 1 | 2011 | 21 | 0.090 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 185 | 0.090 |
Why?
| | Photochemotherapy | 1 | 2011 | 32 | 0.090 |
Why?
| | Biopsy, Fine-Needle | 1 | 2012 | 104 | 0.090 |
Why?
| | Parathyroid Hormone | 1 | 2012 | 143 | 0.090 |
Why?
| | Fascia | 1 | 2010 | 7 | 0.090 |
Why?
| | Lymph Node Excision | 1 | 2012 | 133 | 0.090 |
Why?
| | Laser Coagulation | 1 | 2011 | 26 | 0.080 |
Why?
| | Coloring Agents | 1 | 2011 | 68 | 0.080 |
Why?
| | Carcinoma | 1 | 2012 | 135 | 0.080 |
Why?
| | Models, Biological | 2 | 2011 | 735 | 0.080 |
Why?
| | Tongue Neoplasms | 1 | 2010 | 11 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 485 | 0.080 |
Why?
| | Speech Intelligibility | 1 | 2010 | 14 | 0.080 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2011 | 122 | 0.080 |
Why?
| | Veins | 1 | 2011 | 74 | 0.080 |
Why?
| | Survival Analysis | 1 | 2012 | 656 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2011 | 75 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2012 | 253 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2011 | 461 | 0.080 |
Why?
| | Neural Crest | 1 | 2009 | 3 | 0.080 |
Why?
| | Tracheostomy | 1 | 2010 | 76 | 0.080 |
Why?
| | Quality Indicators, Health Care | 1 | 2010 | 91 | 0.080 |
Why?
| | Xenopus Proteins | 1 | 2009 | 34 | 0.080 |
Why?
| | Risk Assessment | 1 | 2014 | 1349 | 0.080 |
Why?
| | Homeodomain Proteins | 1 | 2009 | 80 | 0.080 |
Why?
| | Wnt Proteins | 1 | 2009 | 102 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2010 | 142 | 0.070 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 297 | 0.070 |
Why?
| | Survival Rate | 1 | 2010 | 944 | 0.070 |
Why?
| | Pneumothorax, Artificial | 1 | 2007 | 1 | 0.070 |
Why?
| | Urologic Surgical Procedures | 1 | 2007 | 30 | 0.070 |
Why?
| | Disease Progression | 1 | 2010 | 870 | 0.070 |
Why?
| | Diaphragm | 1 | 2007 | 33 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2018 | 1045 | 0.060 |
Why?
| | Atrioventricular Node | 1 | 2006 | 5 | 0.060 |
Why?
| | Tachycardia, Ectopic Atrial | 1 | 2006 | 3 | 0.060 |
Why?
| | Schizophrenia | 1 | 2008 | 257 | 0.060 |
Why?
| | Cryosurgery | 1 | 2006 | 36 | 0.060 |
Why?
| | Pilot Projects | 2 | 2022 | 725 | 0.060 |
Why?
| | Azepines | 2 | 2016 | 21 | 0.060 |
Why?
| | Risk Factors | 1 | 2014 | 3971 | 0.060 |
Why?
| | Pulmonary Veins | 1 | 2005 | 42 | 0.060 |
Why?
| | Laparoscopy | 1 | 2007 | 180 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 218 | 0.060 |
Why?
| | Triazoles | 2 | 2016 | 115 | 0.060 |
Why?
| | Animals | 5 | 2024 | 13485 | 0.050 |
Why?
| | Fluoroscopy | 1 | 2024 | 49 | 0.050 |
Why?
| | Genome | 1 | 2024 | 61 | 0.050 |
Why?
| | Video Recording | 1 | 2024 | 79 | 0.050 |
Why?
| | Salivary Ducts | 1 | 2023 | 3 | 0.050 |
Why?
| | Facial Bones | 1 | 2023 | 17 | 0.050 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2023 | 17 | 0.050 |
Why?
| | Parotid Gland | 1 | 2023 | 10 | 0.050 |
Why?
| | Phylogeny | 1 | 2024 | 229 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2024 | 112 | 0.050 |
Why?
| | Atrial Fibrillation | 1 | 2005 | 196 | 0.050 |
Why?
| | Ibuprofen | 1 | 2022 | 24 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2023 | 127 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 2 | 2015 | 60 | 0.050 |
Why?
| | Recurrent Laryngeal Nerve | 1 | 2021 | 12 | 0.040 |
Why?
| | Laryngeal Nerves | 1 | 2021 | 15 | 0.040 |
Why?
| | Glossectomy | 1 | 2021 | 5 | 0.040 |
Why?
| | Tongue | 1 | 2021 | 41 | 0.040 |
Why?
| | Arteries | 1 | 2021 | 93 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2023 | 977 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 1429 | 0.040 |
Why?
| | Mice | 3 | 2016 | 5899 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 1134 | 0.040 |
Why?
| | Pain Management | 1 | 2021 | 187 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 199 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 234 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 316 | 0.040 |
Why?
| | Colonoscopy | 1 | 2018 | 105 | 0.040 |
Why?
| | Immunotherapy | 1 | 2018 | 251 | 0.030 |
Why?
| | Chile | 1 | 2016 | 7 | 0.030 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2016 | 24 | 0.030 |
Why?
| | Digestive System Surgical Procedures | 1 | 2016 | 32 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 109 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 176 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 91 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 134 | 0.030 |
Why?
| | Drug Synergism | 1 | 2016 | 147 | 0.030 |
Why?
| | Mice, SCID | 1 | 2016 | 178 | 0.030 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 18 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 182 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 441 | 0.030 |
Why?
| | Acetylation | 1 | 2015 | 96 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 580 | 0.030 |
Why?
| | Blotting, Western | 1 | 2016 | 587 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 404 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 235 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 248 | 0.030 |
Why?
| | Chromatin | 1 | 2015 | 143 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2016 | 288 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2015 | 168 | 0.030 |
Why?
| | Amino Acid Chloromethyl Ketones | 1 | 2013 | 10 | 0.030 |
Why?
| | Phagosomes | 1 | 2013 | 16 | 0.030 |
Why?
| | Tissue Fixation | 1 | 2013 | 35 | 0.030 |
Why?
| | Paraffin Embedding | 1 | 2013 | 52 | 0.030 |
Why?
| | Formaldehyde | 1 | 2013 | 51 | 0.030 |
Why?
| | Caspases | 1 | 2013 | 101 | 0.030 |
Why?
| | Protein Binding | 1 | 2015 | 673 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2013 | 269 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 465 | 0.020 |
Why?
| | Registries | 1 | 2016 | 638 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1020 | 0.020 |
Why?
| | Preoperative Period | 1 | 2012 | 47 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 462 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 598 | 0.020 |
Why?
| | Postoperative Period | 1 | 2012 | 169 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 62 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 731 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 231 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 130 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 853 | 0.020 |
Why?
| | Lasers | 1 | 2011 | 64 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 601 | 0.020 |
Why?
| | Cancer Care Facilities | 1 | 2010 | 20 | 0.020 |
Why?
| | Leg | 1 | 2011 | 122 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 2987 | 0.020 |
Why?
| | Genes, Homeobox | 1 | 2009 | 7 | 0.020 |
Why?
| | Body Patterning | 1 | 2009 | 12 | 0.020 |
Why?
| | Xenopus | 1 | 2009 | 41 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2009 | 53 | 0.020 |
Why?
| | Biopsy | 1 | 2011 | 594 | 0.020 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 147 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 204 | 0.020 |
Why?
| | beta Catenin | 1 | 2009 | 105 | 0.020 |
Why?
| | Binding Sites | 1 | 2009 | 379 | 0.020 |
Why?
| | Base Sequence | 1 | 2009 | 632 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1365 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 778 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2008 | 47 | 0.020 |
Why?
| | Schizophrenic Psychology | 1 | 2008 | 68 | 0.020 |
Why?
| | Child, Preschool | 1 | 2016 | 4046 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 324 | 0.020 |
Why?
| | Psychometrics | 1 | 2008 | 238 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2007 | 95 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2006 | 85 | 0.020 |
Why?
| | Atrial Function | 1 | 2005 | 7 | 0.010 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2005 | 23 | 0.010 |
Why?
| | Angiography | 1 | 2005 | 111 | 0.010 |
Why?
| | Heart Rate | 1 | 2006 | 311 | 0.010 |
Why?
| | Electrocardiography | 1 | 2006 | 273 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2005 | 125 | 0.010 |
Why?
| | Logistic Models | 1 | 2005 | 930 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 1724 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|